



Rockwell Medical Reports Results for First Quarter 2009

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ERSD), chronic kidney disease (CKD) and iron deficiency anemia, reported first quarter 2009 sales of \$12.8 million, up 3.1% from \$12.4 million for the same period of 2008. Loss for the first quarter 2009 was (\$1.7) million or (\$.12) per share compared to (\$1.2) million or (\$.09) per share for the same period 2008.

First Quarter

- Quarterly sales of \$12.8 million increased 3.1% compared to the first quarter of 2008.
- Domestic sales increased 5.5% compared to the first quarter of 2008.
- Gross profit totaled \$1.2 million compared to \$.7 million in the first quarter of 2008.
- Gross profit margins increased to 9.3% from 5.8% in the first quarter of 2008.
- SFP related R&D expense increased 71% to \$1.3 million compared to \$.8 million in the first quarter 2008.
- Loss of (\$1.7) million compared to loss of (\$1.2) million in the first quarter 2008.

Drug Development Progress

- Completed SFP Phase 2b study enrollment; subject treatments expected to be completed in October.
- Data Safety Monitoring Board (DSMB) review noted no safety concerns with SFP and recommended continuation of Phase 2b study.
- Appointed Richard Yocum, M.D. to VP of Drug Development & Medical Affairs in February 2009.

Mr. Robert L. Chioini, Chairman and CEO stated, "We are pleased with our first quarter performance. We continue to make solid progress clinically. We anticipate our Phase 2b data will be available by year end and that our Phase 3 program will begin sometime thereafter. Both our business and clinical development progress is in line with our expectations."

Rockwell will be hosting a conference call to review its first quarter results and to provide investors with an update on its business development efforts on Wednesday, May 7, 2008 at 11:00 am EST.

Rockwell will be hosting a conference call to review its 2009 first quarter results on Monday, May 11, 2009 at 4:15 pm EDT. Investors are encouraged to call a few minutes in advance at (877) 718-5111 to listen to the call or on the web at:

<http://investor.shareholder.com/media/eventdetail.cfm?eventid=68448&CompanyID=RMTI&e=1&mediaKey=A2FAB283B25BD82A09AC1C359F047CEF>

The call will be available for replay for one week at the same link above.

About SFP:

SFP is a novel, investigational, physiological iron maintenance therapy designed to treat or prevent iron deficiency anemia in ESRD patients. SFP is a proprietary, water-soluble form of iron that travels directly to the bloodstream and transfers iron at a cellular level, similar to normal healthy iron uptake. SFP is designed as a continuous maintenance treatment consisting of small doses administered with every dialysis session to maintain iron status tests stable within target, as per Kidney Disease Quality Outcomes Initiative (KDOQI) recommendations. Clinical trials to date suggest that SFP delivered during each dialysis treatment, via the Company's dialysate, has the ability to maintain optimal iron balance and avoid liver toxicity while decreasing associated pharmaceutical intravenous (IV) iron administration costs. Recent academic studies have shown that more frequent maintenance doses of iron improve the therapeutic response and benefits of recombinant erythropoietin treatments. Rockwell has licensed exclusive world-wide rights and has secured patents for SFP in multiple countries, including the three largest dialysis markets in the world: the United States, Japan, and the European Union. The total U.S. market for IV iron is approximately \$500 million annually while global market potential is approximately \$850 million.

About Rockwell Medical Technologies:

Rockwell is a fully-integrated biopharmaceutical company offering innovative products and services initially targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia. An established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad, Rockwell provides products that are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Dialysis is a process that duplicates kidney function for patients who suffer from ESRD. There are approximately 375,000 ESRD patients in the United States, a number that is growing at an annual rate of 4 percent, and approximately 2 million ESRD patients world-wide.

The Company is currently developing unique, proprietary renal drug therapies for iron treatment. These exclusive renal drug

therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are designed to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell is developing a pipeline of drug therapies, including extensions of SFP for indications outside of hemodialysis.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "projected," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Rockwell's SEC filings. Thus, actual results could be materially different. Rockwell expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Rockwell Medical Technologies, Inc. and Subsidiary Consolidated Income Statements For the three months ended March 31, 2009 and March 31, 2008 (Unaudited)		
	3 Months ended Mar 31, 2009	3 Months ended Mar 31, 2008
Sales	\$ 12,796,772	\$ 12,412,037
Cost of Sales *	<u>11,603,825</u>	<u>11,694,736</u>
Gross Profit	1,192,947	717,301
Selling, General, Admin *	1,560,815	1,289,752
Research & Product Devel.	<u>1,338,310</u>	<u>782,713</u>
Operating (Loss)	(1,706,178)	(1,355,164)
Interest Expense (Income), net	<u>9,265</u>	<u>(144,991)</u>
Net (Loss)	\$ <u>(1,715,443)</u>	\$ <u>(1,210,173)</u>
Basic Earnings (Loss) per share	\$ (0.12)	\$ (0.09)
Diluted Earnings (Loss) per share	\$ (0.12)	\$ (0.09)
Note: *The Company has reclassified certain quality assurance and operations management expenses totaling \$140,000 from selling, general and administrative expense to cost of sales in the 2008 consolidated income statement to conform with the current year presentation.		

Rockwell Medical Technologies, Inc. and Subsidiary
Consolidated Balance Sheets
As of March 31, 2009 and December 31, 2008

	Mar. 31, 2009 (Unaudited)	Dec. 31, 2008
Assets		
Cash and Cash Equivalents	\$ 3,353,468	\$ 5,596,645
Accounts Receivable, net of a reserve of \$83,000 in 2009 and \$97,000 in 2008	4,869,201	5,229,656
Inventory	2,815,829	3,161,625
Other Current Assets	<u>484,898</u>	<u>440,765</u>
Total Current Assets	11,523,396	14,428,691
Property and Equipment, net	3,263,906	3,249,003
Intangible Assets	235,305	240,656
Goodwill	920,745	920,745
Other Non-current Assets	<u>123,387</u>	<u>120,887</u>
Total Assets	<u>\$ 16,066,739</u>	<u>\$ 18,959,982</u>
Liabilities and Shareholders' Equity		
Notes Payable & Capitalized Lease Obligations	139,202	176,850
Accounts Payable	3,834,491	5,210,972
Accrued Liabilities	1,240,579	1,464,828
Customer Deposits	<u>208,751</u>	<u>245,186</u>
Total Current Liabilities	5,423,023	7,097,836
Long Term Notes Payable & Capitalized Lease Obligations	28,976	41,203
Shareholders' Equity:		
Common Shares, no par value, 14,132,712 and 14,104,690 shares issued and outstanding	35,172,916	34,799,093
Common Share Purchase Warrants, 2,134,169 and 2,114,169 shares issued and outstanding	3,513,815	3,378,398
Accumulated Deficit	<u>(28,071,991)</u>	<u>(26,356,548)</u>
Total Shareholders' Equity	<u>10,614,740</u>	<u>11,820,943</u>
Total Liabilities and Shareholders' Equity	<u>\$ 16,066,739</u>	<u>\$ 18,959,982</u>